In addition, Metsera today announced the exercise in full by the underwriters of their option to purchase 2,291,666 additional shares, at the initial public offering price of $18.00 per share ...
We recently published a list of 10 Stocks With At Least $10 Million In Insider Spending Recently. In this article, we are ...
Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...
Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the Nasdaq this year, raising $275 million and $140 million, respectively.
BofA initiated coverage of Metsera (MTSR) with a Buy rating and $38 price target implying over 20% share upside. Metsera is a clinical-stage ...
On February 3, three insiders purchased a total of around $94.22 million worth of Metsera shares during the company’s initial public offering. Insiders acquired shares at a price of $18 per share.
Guggenheim has initiated Metsera at buy saying that the ... mid-year and a monthly dosing profile of MET-097i in late 2025. Initial 097i/233i combination data is also expected late this year.
In addition, Metsera today announced the exercise in full by the underwriters of their option to purchase 2,291,666 additional shares, at the initial public offering price of $18.00 per share, and the ...
In addition, Metsera today announced the exercise in full by the underwriters of their option to purchase 2,291,666 additional shares, at the initial public offering price of $18.00 per share, and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback